Company Filing History:
Years Active: 2023
Title: Unveiling the Innovations of Helty Adisetiyo in the Field of Immune Therapy
Introduction: Helty Adisetiyo, a distinguished inventor based in Culver City, CA, has made significant contributions to the field of immune therapy through his groundbreaking patent on Anti-CD30 monoclonal antibodies and chimeric antigen receptors.
Latest Patents: Adisetiyo's notable patent encompasses antibodies, fragments, and chimeric proteins that exhibit specific binding activity against CD30. These molecules find application in pharmaceutical compositions for immune therapy, particularly benefiting individuals diagnosed with hematopoietic malignancies such as Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, and CD30-positive NK cell lymphomas.
Career Highlights: As a key figure at Nantbio, Inc., Adisetiyo has played a pivotal role in driving innovation and advancing research in the field of immune therapy. His expertise and inventive prowess have led to the development of novel solutions aimed at addressing critical medical needs.
Collaborations: Adisetiyo has collaborated closely with accomplished professionals in the industry, including Clifford Anders Olson and Kayvan R Niazi. Together, they have synergized their expertise to pioneer new advancements in immune therapy, solidifying their position as trailblazers in the field.
Conclusion: Helty Adisetiyo's relentless pursuit of innovation and his visionary approach to immune therapy have significantly impacted the realm of medical science. Through his pioneering work and collaborative efforts, Adisetiyo continues to shape the landscape of immune therapy, offering hope and healing to individuals battling hematopoietic malignancies worldwide.